Paroxysmal cold hemoglobinuria successfully treated with complement inhibition

Blood Adv. 2019 Nov 26;3(22):3575-3578. doi: 10.1182/bloodadvances.2019000897.

Authors

Sarah A Lau-Braunhut¹, Hannah Stone¹, Griffin Collins¹, Sigbjørn Berentsen², Benjamin S Braun¹, Matt S Zinter¹

Affiliations

¹ Department of Pediatrics, University of California, San Francisco, San Francisco, CA; and.
² Department of Research and Innovation, Haugesund Hospital, Haugesund, Norway.

Abstract

This is the first-ever demonstration of successful treatment of paroxysmal cold hemoglobinuria using the complement inhibitor eculizumab.

MeSH terms

Complement Activation / drug effects*
Complement System Proteins / immunology*
Hemoglobinuria, Paroxysmal / blood
Hemoglobinuria, Paroxysmal / diagnosis
Hemoglobinuria, Paroxysmal / immunology*
Hemoglobinuria, Paroxysmal / therapy*
Hemolysis / drug effects
Hemolysis / immunology
Humans
Immunosuppressive Agents / administration & dosage
Immunosuppressive Agents / adverse effects
Immunosuppressive Agents / therapeutic use*
Methylprednisolone / administration & dosage
Methylprednisolone / adverse effects
Methylprednisolone / therapeutic use
Treatment Outcome

Substances

Immunosuppressive Agents
Complement System Proteins
Methylprednisolone